Related Experiment Video
Updated: Nov 20, 2025
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
A Novel AKR1C3 Specific Prodrug TH3424 With Potent Antitumor Activity in Liver Cancer
Ping He1,2, Chunnian Wang3, Yanlan Wang1,2
1School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Abstract:
Overexpression of AKR1C3, an aldo-keto reductase, was recently discovered in liver cancers. In this study, an inverse correlation between AKR1C3 expression and survival of patients with liver cancer was observed. AKR1C3 inhibitors, however, failed to suppress liver cancer cell growth. The prodrug TH3424, which releases a DNA alkylating reagent upon reduction by AKR1C3, was developed to target tumors with overexpression of AKR1C3. TH3424 showed specific killing of liver cancer cells with AKR1C3 overexpression both in vitro and in vivo. In patient-derived mouse xenograft models, TH3424 at doses as low as 1.5 mg/kg eliminated liver tumors with no apparent toxicity. Therefore, TH3424 is a promising drug candidate for liver cancer and other types of cancers overexpressing AKR1C3.
Insights
A new drug, TH3424, effectively targets liver cancer cells overexpressing AKR1C3 (aldo-keto reductase). This promising therapy eliminates tumors with minimal toxicity, offering hope for liver cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Context:
- Overexpression of aldo-keto reductase 1C3 (AKR1C3) is linked to poor prognosis in liver cancer.
- Conventional AKR1C3 inhibitors have shown limited efficacy in suppressing liver cancer cell proliferation.
- Targeting AKR1C3 is a potential therapeutic strategy for liver malignancies.
Purpose:
- To develop and evaluate a novel prodrug, TH3424, designed to selectively target cancer cells with high AKR1C3 expression.
- To assess the efficacy and toxicity of TH3424 in preclinical models of liver cancer.
- To investigate TH3424 as a potential therapeutic agent for AKR1C3-overexpressing cancers.
Summary:
- The study investigated TH3424, a prodrug that releases a DNA alkylating agent when activated by AKR1C3.
- TH3424 demonstrated potent and specific cytotoxicity against liver cancer cells overexpressing AKR1C3 in vitro and in vivo.
- In patient-derived xenograft models, TH3424 eradicated liver tumors at low doses (1.5 mg/kg) without observable toxicity.
Impact:
- TH3424 represents a promising targeted therapy for liver cancer patients with elevated AKR1C3 levels.
- This approach may be applicable to other cancer types that exhibit AKR1C3 overexpression.
- The findings support the clinical development of TH3424 for treating specific cancer indications.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists